Mirjam Boggasch; Ingeborg Eblenkamp; Wolfgang Gabler; Walter Lindenbaum; Gisela Sandner; Markus Sauter; Jochen Scheytt Schroedel Verlag GmbH (2021) Kovakantinen kirja
Edward Elgar Sivumäärä: 324 sivua Asu: Kovakantinen kirja Julkaisuvuosi: 2022, 15.11.2022 (lisätietoa) Kieli: Englanti
This timely book discusses the application of the EU competition rules to pharmaceuticals, covering the prohibitions on anticompetitive agreements and abuse of dominance, and merger control.
The author team comprises academic experts and private practitioners who analyse recent case law at both EU (and UK) and Member State levels – in the context of current issues and future trends, including those related to COVID-19 – and examine the impact of competition law on the behaviour of the pharmaceutical industry. The book carefully considers the balance between competition and innovation, as well as between competition and regulation. It concludes that competition and regulation are not alternatives, but complementary, and that novel ways of taking into account risk and real innovation through competition assessments have been developed.
Integrating an overview of competition law, IP law and pharmaceutical regulation, this book will be an ideal read for scholars and graduate students, as well as private and public practitioners interested in pharmaceutical and European law.
